ADAPTIMMUNE THERAPEUTICS PLC Contract Liability (Deferred Revenue)
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) had Contract Liability (Deferred Revenue) of $10.70 million as of 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-08-13
- 2025-06-30: Contract with Customer, Liability, Current $10.70M.
- 2025-03-31: Contract with Customer, Liability, Current $12.44M.
- 2024-12-31: Contract with Customer, Liability, Current $12.30M.
- 2024-09-30: Contract with Customer, Liability, Current $18.71M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2025-06-30 | $10.70M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $12.44M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $12.30M 10-Q · filed 2025-08-13 |
| 2024-09-30 | $18.71M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $38.42M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $31.52M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $28.97M 10-K · filed 2025-03-24 |
| 2023-09-30 | $29.31M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $31.42M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $22.30M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $23.52M 10-K · filed 2024-03-06 |
| 2022-09-30 | $20.62M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $22.47M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $24.77M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $22.20M 10-K · filed 2023-03-06 |
| 2021-09-30 | $6.10M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $4.91M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.08M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $2.83M 10-K · filed 2022-03-14 |
| 2020-09-30 | $3.63M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.46M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.66M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $2.13M 10-K · filed 2021-02-25 |
| 2019-09-30 | $2.68M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $3.02M 10-Q · filed 2019-08-01 |
| 2018-09-30 | $1.34M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $16.72M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $27.22M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $38.73M 10-Q · filed 2018-11-06 |